Skip to main content
. 2021 Apr 23;9:73–86. doi: 10.21307/sjcapp-2021-009

TABLE 2.

Characteristics of treatment with previous MPH medications and DEX

Previous MPH treatment
Number of MPH therapies, n (%) (N=137)
    1 118 (86.1)
    2 15 (11.0)
    3 3 (2.2)
    5 1 (0.7)
Number of single doses per day, mean ± SD (N=137) 1.4 ± 0.5
    Immediate-release (N=33) 1.5 ± 0.6
    Extended-release (N=114) 1.4 ± 0.5
Total daily MPH dose (mg), mean ± SD (N=137) 27.5 ± 14.1
    Immediate-release (N=33) 20.7 ± 12.2
    Extended-release (N=114) 28.9 ± 14.0
DEX treatment
Total daily dose at the respective visit (mg), median (IQR)
    First titration visit (initial dose) (N=138) 5.0 (5.0)
        Children (<12 years) (N=80) 5.0 (5.0)
        Adolescents (≥12 years) (N=58) 5.0 (5.0)
    Titration (last recorded dose) (N=138) 11.3 (10.0)
        Children (<12 years) (N=80) 10.0 (10.6)
        Adolescents (≥12 years) (N=58) 15.0 (10.0)
    V2 (N=95) 12.5 (10.0)
        Children (<12 years) (N=57) 10.0 (10.0)
        Adolescents (≥12 years) (N=38) 15.0 (10.0)
    V3 (N=82) 15.0 (10.0)
        Children (<12 years) (N=53) 12.5 (10.0)
        Adolescents (≥12 years) (N=29) 20.0 (10.0)
Optimal total daily dose (mg), median (IQR) (N=120) 10.0 (10.0)
    Children (<12 years) (N=69) 10.0 (10.0)
    Adolescents (≥12 years) (N=51) 15.0 (10.0)
Optimal total daily dose per body weight (mg/kg), median (IQR) (N=120) 0.3 (0.3)
    Children (<12 years) (N=69) 0.4 (0.3)
    Adolescents (≥12 years) (N=51) 0.3 (0.2)
Number of titration steps to optimal total daily dose, n (%) (N=140)
    1 16 (11.4)
    2 46 (32.9)
    3 24 (17.1)
    4 22 (15.7)
    5 4 (2.9)
    6 7 (5.0)
    10 1 (0.7)
    Optimal total daily dose not achieved 18 (12.9)
    No titration performed 2 (1.4)
Dose regimen, n (%) (N=129)
    Once daily 76 (58.9)
    Twice daily 50 (38.8)
    Three times daily 2 (1.6)
    Four times daily 1 (0.8)

Notes. DEX: Dexamphetamine; IQR: Interquartile range; MPH: Methylphenidate; SD: Standard deviation